CRF receptors in the rodent and human cardiovascular systems: Species differences

Peptides

Volumn 27, Issue 12, 2006, Pages 3029-3038

  Waser, Beatrice ^a   Rehmann, Ruth ^a   Rivier, Jean ^b   Vale, Wylie ^b   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Cardiovascular system; CRF receptors; Species differences

Indexed keywords

ANTISAUVAGINE 30; CORTICOTROPIN RELEASING FACTOR RECEPTOR; TRACER;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLADDER; BRAIN; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEART; HEART MUSCLE; HUMAN; HUMAN TISSUE; INTESTINE; KIDNEY; LUNG; MESENTERY; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR DENSITY; TESTIS; TISSUE DISTRIBUTION;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SPECIES SPECIFICITY;

RODENTIA;

EID: 33750941897     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.07.005     Document Type: Article

References (33)

1. Bale T.L., Giordano F.J., Hickey R.P., Huang Y., Nath A.K., Peterson K.L., et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99 (2002) 7734-7739
2. Coste S.C., Heldwein K.A., Stevens S.L., Tobar-Dupres E., and Stenzel-Poore M.P. IL-1alpha and TNFalpha down-regulate CRH receptor-2 mRNA expression in the mouse heart. Endocrinology 142 (2001) 3537-3545
3. Davis M.E., Pemberton C.J., Yandle T.G., Lainchbury J.G., Rademaker M.T., Nicholls M.G., et al. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 109 (2005) 381-388
4. Davis M.E., Pemberton C.J., Yandle T.G., Lainchbury J.G., Rademaker M.T., Nicholls M.G., et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89 (2004) 1402-1409
5. De Souza E.B., and Kuhar M.J. Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: methods and overview. Methods Enzymol 124 (1986) 560-590
6. Denzler B., and Reubi J.C. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85 (1999) 188-198
7. Eckart K., Jahn O., Radulovic J., Radulovic M., Blank T., Stiedl O., et al. Pharmacology and biology of corticotropin-releasing factor (CRF) receptors. Receptors Channels 8 (2002) 163-177
8. Grammatopoulos D.K., and Chrousos G.P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13 (2002) 436-444
9. Grunt M., Haug C., Duntas L., Pauschinger P., Maier V., and Pfeiffer E.F. Dilatory and inotropic effects of corticotropin-releasing factor (CRF) on the isolated heart. Effects on atrial natriuretic peptide (ANP) release. Horm Metab Res 24 (1992) 56-59
10. Hermus A.R., Pieters G.F., Willemsen J.J., Ross H.A., Smals A.G., Benraad T.J., et al. Hypotensive effects of ovine and human corticotrophin-releasing factors in man. Eur J Clin Pharmacol 31 (1987) 531-534
11. Jain V., Longo M., Ali M., Saade G.R., Chwalisz K., and Garfield R.E. Expression of receptors for corticotropin-releasing factor in the vasculature of pregnant rats. J Soc Gynecol Investig 7 (2000) 153-160
12. Kimura Y., Takahashi K., Totsune K., Muramatsu Y., Kaneko C., Darnel A.D., et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87 (2002) 340-346
13. Lei S., Richter R., Bienert M., and Mulvany M.J. Relaxing actions of corticotropin-releasing factor on rat resistance arteries. Br J Pharmacol 108 (1993) 941-947
14. Lenz H.J., Fisher L.A., Vale W.W., and Brown M.R. Corticotropin-releasing factor, sauvagine, and urotensin I: effects on blood flow. Am J Physiol 249 (1985) R85-R90
15. Liaw C.W., Lovenberg T.W., Barry G., Oltersdorf T., de Souza D.E., and Oltersdorf B.B. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137 (1996) 72-77
16. Lovenberg T.W., Chalmers D.T., Liu C., and De Souza E.B. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136 (1995) 4139-4142
17. MacCannell K.L., Hamilton P.L., Lederis K., Newton C.A., and Rivier J. Corticotropin releasing factor-like peptides produce selective dilatation of the dog mesenteric circulation. Gastroenterology 87 (1984) 94-102
18. Parkes D.G., Vaughan J., Rivier J., Vale W., and May C.N. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 272 (1997) H2115-H2122
19. Parkes D.G., Weisinger R.S., and May C.N. Cardiovascular actions of CRH and urocortin: an update. Peptides 22 (2001) 821-827
20. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 92 (1995) 2969-2973
21. Perrin M.H., Sutton S.W., Cervini L.A., Rivier J.E., and Vale W.W. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther 288 (1999) 729-734
22. Reubi J.C., Gugger M., Waser B., and Schaer J.C. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61 (2001) 4636-4641
23. Reubi J.C., Läderach U., Waser B., Gebbers J.-O., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60 (2000) 3105-3112
24. Reubi J.C., Waser B., Vale W., and Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88 (2003) 3312-3320
25. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98 (2001) 2843-2848
26. Rivier J, Gulyas J, Kirby D, Kunitake K, DiGruccio M, Donaldson C, et al. Receptor-selective corticotropin releasing factor analogs. Proc. Meeting of the Society for Neuroscience. San Diego, CA; 2001. Session number: p. 413.17. In press.
27. Rivier J., Gulyas J., Kirby D., Low W., Perrin M.H., Kunitake K., et al. Potent and long acid corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45 (2002) 4737-4747
28. Sanz E., Monge L., Fernandez N., Martinez M.A., Martinez-Leon J.B., Dieguez G., et al. Relaxation by urocortin of human saphenous veins. Br J Pharmacol 136 (2002) 90-94
29. Simoncini T., Apa R., Reis F.M., Miceli F., Stomati M., Driul L., et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 84 (1999) 2802-2806
30. Tao J., and Li S. Effects of urocortin via ion mechanisms or CRF receptors?. Biochem Biophys Res Commun 336 (2005) 731-736
31. Udelsman R., Harwood J.P., Millan M.A., Chrousos G.P., Goldstein D.S., Zimlichman R., et al. Functional corticotropin releasing factor receptors in the primate peripheral sympathetic nervous system. Nature 319 (1986) 147-150
32. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
33. Wiley K.E., and Davenport A.P. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143 (2004) 508-514